Purchase this article with an account.
Nicole Stuebiger; Low dose acetyl salicyl acid as a treatment option for central serous chorioretinopathy. Invest. Ophthalmol. Vis. Sci. 2013;54(15):1962.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Since an increased plasminogen activator inhibitor 1 (PAJ-1) was found being associated with central serous chorioretinopathy (CSCR) it was the rationale for treating CSCR patients with acetyl salicylic acid, which has a PAJ-1 lowering effect. We evaluated the effectiveness of low-dose acetyl salicylic acid in patients with CSCR.
Patients with classical or multifocal CSCR were treated with low dose acetyl salicylic acid (aspirin). The patients received 100mg per day orally for one month followed by 100mg every other day for the following 5 months. The effect of this therapy was evaluated in 5 patients (6 eyes). Visual acuity, metamorphopsia, and central retinal thickness quantified by ocular coherence tomography (OCT) were recorded at baseline and follow-up visits.
After a mean follow up time of 7.8 months we could receive improvement of visual acuity in 5 eyes, only one eye disclosed an unchanged visual acuity (mean visual acutiy rose from 0.66 before therapy to 0.89 at the end ot the therapeutic phase). The central retinal sicknes was reduced during treatment and fell from a mean of 568 µm to 273 µm. There were no adverse events related to the administration of aspirin.
Although there may have been a spontaneous improvement without treatment, acetyl salicyl acid showed effectiveness and has a plausible mechanism in CSCR.
This PDF is available to Subscribers Only